WO2006054319A3 - Utilisation de formulations a base de chito-oligomeres pour modifier l'activite anormale des proteines de type chitinase - Google Patents

Utilisation de formulations a base de chito-oligomeres pour modifier l'activite anormale des proteines de type chitinase Download PDF

Info

Publication number
WO2006054319A3
WO2006054319A3 PCT/IS2005/000024 IS2005000024W WO2006054319A3 WO 2006054319 A3 WO2006054319 A3 WO 2006054319A3 IS 2005000024 W IS2005000024 W IS 2005000024W WO 2006054319 A3 WO2006054319 A3 WO 2006054319A3
Authority
WO
WIPO (PCT)
Prior art keywords
chitinase
proteins
chitooligomer
formulations
abnormal activity
Prior art date
Application number
PCT/IS2005/000024
Other languages
English (en)
Other versions
WO2006054319A2 (fr
Inventor
Olafur B Einarsson
Jon M Einarsson
Johannes Gislason
Finnbogi R Thormodsson
Original Assignee
Genis Ehf
Olafur B Einarsson
Jon M Einarsson
Johannes Gislason
Finnbogi R Thormodsson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genis Ehf, Olafur B Einarsson, Jon M Einarsson, Johannes Gislason, Finnbogi R Thormodsson filed Critical Genis Ehf
Publication of WO2006054319A2 publication Critical patent/WO2006054319A2/fr
Publication of WO2006054319A3 publication Critical patent/WO2006054319A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/722—Chitin, chitosan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une utilisation, une composition et un procédé pour le traitement des troubles ou maladies dégénératifs des tissus ou du tissu conjonctif, du système nerveux central, des tissus cardiovasculaires ou du système immunitaire. La composition de cette invention comprend des chito-oligomères visant à réduire l’expression anormalement élevée de protéines de type chitinase chez des patients souffrant de troubles ou de maladies associés au tissu conjonctif, au système nerveux central, aux tissus cardiovasculaires ou au système immunitaire.
PCT/IS2005/000024 2004-11-19 2005-11-21 Utilisation de formulations a base de chito-oligomeres pour modifier l'activite anormale des proteines de type chitinase WO2006054319A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IS7540 2004-11-19
IS7540 2004-11-19

Publications (2)

Publication Number Publication Date
WO2006054319A2 WO2006054319A2 (fr) 2006-05-26
WO2006054319A3 true WO2006054319A3 (fr) 2007-03-08

Family

ID=36182413

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IS2005/000024 WO2006054319A2 (fr) 2004-11-19 2005-11-21 Utilisation de formulations a base de chito-oligomeres pour modifier l'activite anormale des proteines de type chitinase

Country Status (1)

Country Link
WO (1) WO2006054319A2 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057144A (en) * 1997-12-02 2000-05-02 Director Of National Food Research Institute, Ministry Of Agriculture, Forestry And Fisheries Chitin deacetylase gene, vector containing said gene and transformant
WO2003051376A1 (fr) * 2001-12-14 2003-06-26 Ism Biopolymer Inc. Oligosaccharides de chitosane et utilisations correspondantes
US20050112750A1 (en) * 2003-06-27 2005-05-26 Michael Howard Chitin degradative systems

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6057144A (en) * 1997-12-02 2000-05-02 Director Of National Food Research Institute, Ministry Of Agriculture, Forestry And Fisheries Chitin deacetylase gene, vector containing said gene and transformant
WO2003051376A1 (fr) * 2001-12-14 2003-06-26 Ism Biopolymer Inc. Oligosaccharides de chitosane et utilisations correspondantes
US20050112750A1 (en) * 2003-06-27 2005-05-26 Michael Howard Chitin degradative systems

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
"antitumor effect of hexa N acetylchitohexaose and chitohexaose", CARBOHYDRATE RESEARCH, 1986, 151, 403-408, 1986, XP008068779 *
"antitumour activity of chitosan oligosaccharides produced in ultrafiltration membrane reactor system", JOURNAL OF MICROBIOLOGY AND BIOTECHNOLOGY, 2002, 12, 503-507, 2002, XP008068764 *
IWATA H ET AL: "EFFECTS OF CHITOSAN OLIGOSACCHARIDES ON THE FEMUR TRABECULAR STRUCTURE IN OVARIECTOMIZED RATS", ORAL RADIOLOGY, ELSEVIER, AMSTERDAM, NL, vol. 21, no. 1, 2005, pages 19 - 22, XP008062990, ISSN: 0911-6028 *
JUNG ET AL: "Effect of chitooligosaccharides on calcium bioavailability and bone strength in ovariectomized rats", LIFE SCIENCES, PERGAMON PRESS, OXFORD, GB, vol. 78, no. 9, 25 January 2006 (2006-01-25), pages 970 - 976, XP005256147, ISSN: 0024-3205 *
KAZUO: "production and utilization of oligosaccharides from chitin and chitosan", DENPUM KAGAKU, 1990, 37, 79-86, 1990, XP008068765 *
PARK: "Angiotensin I converting enzyme...", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, vol. 51, 2003, pages 4930 - 4934, XP008068755 *
ZHAO, WEAVER: "nondigestible oligosaccharides...", JOURNAL OF NUTRITION, vol. 134, February 2004 (2004-02-01), pages 399 - 402, XP008068757 *

Also Published As

Publication number Publication date
WO2006054319A2 (fr) 2006-05-26

Similar Documents

Publication Publication Date Title
WO2007061661A3 (fr) Inhibiteurs de la 11-beta-hydroxy steroide deshydrogenase de type 1
EP1485381B8 (fr) Azolylaminoazines en tant qu'inhibiteurs de proteines kinases
AU2003220299A1 (en) Azinylaminoazoles as inhibitors of protein kinases
AU2003218215A1 (en) Azolylaminoazines as inhibitors of protein kinases
AU2003220300A1 (en) Compositions useful as inhibitors of protein kinases
WO2006001877A3 (fr) Composition pharmaceutique et methode de traitement de troubles neurodegeneratifs
WO2005028475A3 (fr) Compositions utiles pour inhiber des proteines kinases
WO2006093348A3 (fr) Procede et composition destines au traitement des maladies vasculaires peripheriques
WO2004071529A3 (fr) Utilisations d'anticorps contre le recepteur de facteur de croissance insulinoide i
TW200633980A (en) Pyridones useful as inhibitors of kinases
HK1096673A1 (en) Compositions useful as inhibitors of protein kinases
WO2004069190A3 (fr) Therapie combinee destinee au traitement de troubles associes a une carence proteique
WO2001087328A3 (fr) Inhibiteurs d"interleukine 1 dans le traitement de maladies
WO2007002390A3 (fr) Compositions et procédés de modulation de l’épissage de smn2
WO2005116088A3 (fr) Methodes et compositions pour traiter des maladies et des troubles associes a des cellules exprimant siglec-8
WO2006047516A3 (fr) Composes et compositions servant d'inhibiteurs d'activite de recepteur cannabinoide de type 1
WO2004078116A3 (fr) Inhibiteurs de la p 38 et leurs procedes d'utilisation
WO2006071802A3 (fr) Traitement de l'ictus cerebral et d'autres troubles neurodegeneratifs aigus a base de cellules tirees de tissus puerperaux
WO2007127505A3 (fr) Composés chimiques
EP2319925A3 (fr) Utilisations thérapeutiques d'inhibiteurs du RTP801
WO2005023185A3 (fr) Compositions pharmaceutiques et procede d'utilisation de la levodopa et de la carbidopa
WO2003014309A3 (fr) Recepteurs de l'interleukine-1 dans le traitement de maladies
TW200621765A (en) Substituted phenylaminothiazoles and their use
WO2005056547A3 (fr) Quinoxalines utiles comme inhibiteurs des proteines kinases
WO2004043341A3 (fr) Traitement pour choc hémorragique

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KM KN KP KR KZ LC LK LR LS LT LU LV LY MA MD MG MK MN MW MX MZ NA NG NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SM SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LT LU LV MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 05803140

Country of ref document: EP

Kind code of ref document: A2